These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Chemotherapeutic strategies against Trypanosoma brucei: drug targets vs. drug targeting. Lüscher A; de Koning HP; Mäser P Curr Pharm Des; 2007; 13(6):555-67. PubMed ID: 17346174 [TBL] [Abstract][Full Text] [Related]
4. Activity of Aromathecins against African Trypanosomes. Nenortas NP; Cinelli MA; Morrell AE; Cushman M; Shapiro TA Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30104277 [TBL] [Abstract][Full Text] [Related]
5. Development of novel drugs for human African trypanosomiasis. Brun R; Don R; Jacobs RT; Wang MZ; Barrett MP Future Microbiol; 2011 Jun; 6(6):677-91. PubMed ID: 21707314 [TBL] [Abstract][Full Text] [Related]
6. Drug resistance in Trypanosoma brucei spp., the causative agents of sleeping sickness in man and nagana in cattle. Matovu E; Seebeck T; Enyaru JC; Kaminsky R Microbes Infect; 2001 Jul; 3(9):763-70. PubMed ID: 11489425 [TBL] [Abstract][Full Text] [Related]
7. 25 years of African trypanosome research: From description to molecular dissection and new drug discovery. Matthews KR Mol Biochem Parasitol; 2015; 200(1-2):30-40. PubMed ID: 25736427 [TBL] [Abstract][Full Text] [Related]
8. Targeting the HSP60/10 chaperonin systems of Trypanosoma brucei as a strategy for treating African sleeping sickness. Abdeen S; Salim N; Mammadova N; Summers CM; Goldsmith-Pestana K; McMahon-Pratt D; Schultz PG; Horwich AL; Chapman E; Johnson SM Bioorg Med Chem Lett; 2016 Nov; 26(21):5247-5253. PubMed ID: 27720295 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of anti-sleeping-sickness drugs and topoisomerase inhibitors in combination on Trypanosoma brucei. Steverding D; Wang X J Antimicrob Chemother; 2009 Jun; 63(6):1293-5. PubMed ID: 19336455 [No Abstract] [Full Text] [Related]
13. Closing in on a new treatment for sleeping sickness. Derbyshire ER; Clardy J Elife; 2013 Jul; 2():e01042. PubMed ID: 23853715 [TBL] [Abstract][Full Text] [Related]
14. In vitro evaluation of arylsubstituted imidazoles derivatives as antiprotozoal agents and docking studies on sterol 14α-demethylase (CYP51) from Trypanosoma cruzi, Leishmania infantum, and Trypanosoma brucei. Rojas Vargas JA; López AG; Pérez Y; Cos P; Froeyen M Parasitol Res; 2019 May; 118(5):1533-1548. PubMed ID: 30903349 [TBL] [Abstract][Full Text] [Related]
15. Independence from Kinetoplast DNA maintenance and expression is associated with multidrug resistance in Trypanosoma brucei in vitro. Gould MK; Schnaufer A Antimicrob Agents Chemother; 2014 May; 58(5):2925-8. PubMed ID: 24550326 [TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo anti-Trypanosoma brucei activities of phenazinomycin and related compounds. Otoguro K; Ishiyama A; Iwatsuki M; Namatame M; Nishihara-Tukashima A; Nakashima T; Shibahara S; Kondo S; Yamada H; Omura S J Antibiot (Tokyo); 2010 Sep; 63(9):579-81. PubMed ID: 20588299 [No Abstract] [Full Text] [Related]
17. Parasitology. Drugs to combat tropical protozoan parasites. Gelb MH; Hol WG Science; 2002 Jul; 297(5580):343-4. PubMed ID: 12130767 [No Abstract] [Full Text] [Related]
18. 3-(Oxazolo[4,5-b]pyridin-2-yl)anilides as a novel class of potent inhibitors for the kinetoplastid Trypanosoma brucei, the causative agent for human African trypanosomiasis. Ferrins L; Rahmani R; Sykes ML; Jones AJ; Avery VM; Teston E; Almohaywi B; Yin J; Smith J; Hyland C; White KL; Ryan E; Campbell M; Charman SA; Kaiser M; Baell JB Eur J Med Chem; 2013 Aug; 66():450-65. PubMed ID: 23831695 [TBL] [Abstract][Full Text] [Related]
19. Flavonoid-derived Privileged Scaffolds in anti-Trypanosoma brucei Drug Discovery. Boniface PK; Elizabeth FI Curr Drug Targets; 2019; 20(12):1295-1314. PubMed ID: 31215385 [TBL] [Abstract][Full Text] [Related]